Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy

Takao Hamamoto
ORCID logo ,
Kazuki Sato
,
Kohei Yumii
,
Nobuyuki Chikuie
,
Takayuki Taruya
,
Yuichiro Horibe
,
Takashi Ishino
ORCID logo ,
Tsutomu Ueda
,
Sachio Takeno
* ORCID logo ,
Kenichi Yoshimura
Version 1 : Received: 2 June 2023 / Approved: 6 June 2023 / Online: 6 June 2023 (11:37:29 CEST)

A peer-reviewed article of this Preprint also exists.

Hamamoto, T.; Sato, Y.; Yumii, K.; Chikuie, N.; Taruya, T.; Horibe, Y.; Ishino, T.; Ueda, T.; Takeno, S.; Yoshimura, K. Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy. J. Pers. Med. 2023, 13, 1129. Hamamoto, T.; Sato, Y.; Yumii, K.; Chikuie, N.; Taruya, T.; Horibe, Y.; Ishino, T.; Ueda, T.; Takeno, S.; Yoshimura, K. Evaluation of the Safety of Percutaneous Sensory Nerve Stimulation in Patients with Head and Neck Cancer Receiving Chemoradiotherapy. J. Pers. Med. 2023, 13, 1129.

Abstract

Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck cancer; however, CRT may cause post-treatment dysphagia. Transcutaneous electrical sensory stimulation (TESS), developed in recent years for swallowing rehabilitation, has been used at many medical facilities. Although TESS has been used for dysphagia in several fields, its safety and efficacy in patients with head and neck cancer remain to be clarified. Therefore, this study evaluated the safety of TESS in ten patients with head and neck cancers undergoing CRT. Swallowing rehabilitation intervention and TESS implementation were performed for all patients during CRT. Non-blood toxicity adverse events (AEs), such as dermatitis and mucositis, occurred during CRT; however, the severity was less than Grade 3. No patient experienced pain due to TESS. As survival time analysis using the Kaplan–Meier method for interferential current device implementation rates revealed a feasibility of 100% for up to 60 Gy and a feasibility of 78% for up to 70 Gy, it concludes that TESS was feasible until 70 Gy. This study confirmed the feasibility and safety of TESS in the head and neck region, even during CRT. Although the precise mechanism of TESS on dysphagia is not yet clear, its continued use has great potential for improving sensory disturbance.

Keywords

head and neck neoplasms; electric stimulation; chemoradiotherapy; swallowing; dysphagia

Subject

Medicine and Pharmacology, Otolaryngology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.